Cutlass Capital

Cutlass Capital is a venture capital firm founded in 2001, headquartered in Boston, Massachusetts, with an additional office in San Francisco, California. The firm specializes in investments within the healthcare industry, focusing on life sciences, medical devices, and healthcare supplies. By targeting these sectors, Cutlass Capital aims to support innovative companies that are advancing healthcare solutions and technologies.

Charles Larkin Jr.

Venture Partner

Jonathan Osgood

Co-Founder and Managing Member

13 past transactions

NeuroPace

Venture Round in 2011
NeuroPace, Inc. is a commercial-stage medical device company based in Mountain View, California, that specializes in the treatment of neurological disorders through innovative implantable devices. Founded in 1997, NeuroPace has developed the Responsive Neurostimulator (RNS) System, which is designed to monitor and respond to brain activity in patients with medically refractory partial epilepsy. The RNS System includes a small implantable neurostimulator connected to leads placed in seizure onset areas, delivering targeted electrical pulses to help reduce or eliminate seizures. NeuroPace primarily generates revenue from the sales of its RNS System to hospitals and specialized medical facilities that perform the implantation procedures.

Hemosphere

Series A in 2010
Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.

GI Dynamics

Series C in 2009
GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

Xoft

Series E in 2008
Xoft, Inc. specializes in the development of electronic brachytherapy (eBx) systems designed for radiation oncology applications. The company’s flagship product, the Axxent Controller, employs a miniaturized high dose rate X-ray source to deliver targeted radiation directly to cancerous tumor beds. Xoft also provides a range of applicators, including the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, the company offers a variety of accessories to support its products, such as physics accessory kits and protective shields to minimize radiation exposure to healthy tissues. Xoft’s innovative solutions are primarily utilized in the treatment of early-stage breast cancer, skin cancer, and endometrial cancer, and the products are distributed through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, Xoft was previously known as Xoft microTube, Inc. before rebranding in 2004.

CardioKinetix

Series C in 2008
CardioKinetix, Inc. is a medical technology company based in Menlo Park, California, specializing in the development of transcatheter implants aimed at treating heart failure. The company's flagship product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients suffering from ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, which may benefit millions of patients worldwide. CardioKinetix primarily serves customers in various countries, including the United States, France, Germany, and the United Kingdom. The company was incorporated in 2002 and is dedicated to advancing heart failure treatment through innovative technology.

Evalve

Series D in 2007
Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

Xoft

Series C in 2006
Xoft, Inc. specializes in the development of electronic brachytherapy (eBx) systems designed for radiation oncology applications. The company’s flagship product, the Axxent Controller, employs a miniaturized high dose rate X-ray source to deliver targeted radiation directly to cancerous tumor beds. Xoft also provides a range of applicators, including the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, the company offers a variety of accessories to support its products, such as physics accessory kits and protective shields to minimize radiation exposure to healthy tissues. Xoft’s innovative solutions are primarily utilized in the treatment of early-stage breast cancer, skin cancer, and endometrial cancer, and the products are distributed through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, Xoft was previously known as Xoft microTube, Inc. before rebranding in 2004.

Xoft

Series C in 2005
Xoft, Inc. specializes in the development of electronic brachytherapy (eBx) systems designed for radiation oncology applications. The company’s flagship product, the Axxent Controller, employs a miniaturized high dose rate X-ray source to deliver targeted radiation directly to cancerous tumor beds. Xoft also provides a range of applicators, including the Axxent balloon applicator for accelerated partial breast irradiation, the Axxent vaginal applicator for vaginal brachytherapy, and the Axxent surface applicator for treating surface lesions. Additionally, the company offers a variety of accessories to support its products, such as physics accessory kits and protective shields to minimize radiation exposure to healthy tissues. Xoft’s innovative solutions are primarily utilized in the treatment of early-stage breast cancer, skin cancer, and endometrial cancer, and the products are distributed through physicians and distributors across Europe. Founded in 1998 and based in Sunnyvale, California, Xoft was previously known as Xoft microTube, Inc. before rebranding in 2004.

Evalve

Series C in 2004
Evalve, Inc. engages in the design, development, manufacture, and marketing of devices that enable the repair of cardiac valves. It provides a non-surgical mitral valve repair system consisting of a steerable guide catheter, a clip delivery system, and an implant device that is used by interventional cardiologists to reduce mitral regurgitation. The company was incorporated in 1999 and is based in Menlo Park, California.

GI Dynamics

Series B in 2004
GI Dynamics, Inc. is a medical device company that specializes in designing, developing, and manufacturing non-surgical therapies for the treatment of type 2 diabetes and obesity. The company’s primary product, EndoBarrier, is aimed at helping patients manage their condition and reduce obesity without the need for surgical intervention. GI Dynamics serves healthcare providers and third-party distributors, selling its products mainly in Europe, the Middle East, the Asia Pacific, and South America. Founded in 2003, the company is headquartered in Lexington, Massachusetts.

TranS1

Series B in 2003
TranS1 is a medical device company that specializes in advanced surgical medicine. Founded in 2002, the company is headquartered in Denver, Colorado, and operates as a subsidiary of The Quandary Group. TranS1 focuses on developing a range of medical products and intellectual property aimed at improving surgical procedures and patient outcomes.

Alere

Venture Round in 2003
Alere Inc., formerly known as Inverness Medical Innovations, is a company that specializes in diagnostics and health management solutions. It focuses on infectious disease, cardiology, oncology, drugs of abuse, and women's health, offering a wide array of products and services. Alere's portfolio includes over-the-counter tests, lab-based diagnostics, and integrated home monitoring solutions, with notable brands such as Acceava Mono cassette, Alere Home Monitoring, AtheNA Multi-Lyte Test System, and BinaxNOW. The company operates across multiple regions, including North America, Europe, the Middle East, Asia Pacific, and Latin America and Africa. Its medical diagnostic products aim to facilitate the detection of diseases and conditions, empowering patients and healthcare providers to collaboratively manage health outcomes throughout the continuum of care from hospitals to home settings.

IntelliCare

Series B in 2002
Providing 24-hour healthcare these days is a tough balancing act. Don't perform without a safety net you can trust. At IntelliCare, they know the ropes. They're a management company for medical call centers, and they work closely with health systems, provider networks and physician groups to make their operations a success. They offer experience, flexibility, commitment -- and a wide range of 24-hour telephonic and Web-based medical call center services that let you focus on what you do best. Making people feel better.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.